Company Encyclopedia
View More
name
Biomedical B
CP20027.HK
News
View More

Venus MedTech Reports Positive Interim Results for Cardiovalve Tricuspid Valve Replacement System

Venus MedTech announced positive interim clinical results from its Target Study on the Cardiovalve transcatheter tricuspid valve replacement system. The study involved 125 patients across 25 sites in Germany, Spain, Italy, Canada, and the UK. The interim data showed an average device operation time of 58±29 minutes. The system demonstrated strong efficacy in treating severe tricuspid regurgitation and received positive recognition from global clinical experts. Venus MedTech remains committed to advancing its global clinical development and regulatory registration of Cardiovalve.

Reuters·
HK
02500
+5.26%
Reuters·
HK
02500
+5.26%

Shenwan Hongyuan Sticks to Their Buy Rating for InnoCare Pharma Ltd. (9969)

Shenwan Hongyuan analyst maintained a Buy rating on InnoCare Pharma Ltd. yesterday and set a price target of HK$19.00.Meet Your ETF AI Analyst Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow. InnoCare Pharma Ltd. has an analyst consensus of Strong Buy, with a price target consensus of HK$23.20.

Tip Ranks·
SH
688428
-1.27%
HK
09969
+0.41%
Tip Ranks·
SH
688428
-1.27%
HK
09969
+0.41%

UBS lists predictions for Chinese stocks with high profit growth potential for next year (Table)

UBS released a strategy report on the Chinese market, listing Chinese stocks with high profit growth potential for next year and giving them a "Buy" rating. The list includes Hong Kong stocks and Chinese concept stocks, such as InnoCare Pharma, Kintor Pharmaceutical, Zai Lab, Akeso, ECARX Holdings, CanSinoBIO, Zhongsheng Holdings, BeiGene, Li Auto, GDS Holdings, and iQIYI

AASTOCKS·
US
ZLAB
-2.10%
HK
09688
+0.25%
SH
688185
-1.43%
AASTOCKS·
US
ZLAB
-2.10%
HK
09688
+0.25%
SH
688185
-1.43%

12:31 ET Cardiovalve reicht nach erfolgreichem Abschluss der TARGET-Studie CE-Antrag zur Zulassung ein

Cardiovalve, a subsidiary of Venus Medtech, has submitted technical documents for CE marking of its Transcatheter Tricuspid Valve Replacement (TTVR) system to DEKRA. This follows the successful TARGET study, which demonstrated the safety and efficacy of the Cardiovalve system in treating tricuspid regurgitation. The study involved 150 patients and showed promising results, leading to hopes for a new treatment option for TR patients. Cardiovalve aims for commercial launch by 2027.

prnewswire·
HK
02500
+5.26%
prnewswire·
HK
02500
+5.26%

Alphamab Oncology Files Next Day Disclosure Return to HKEX for Repurchase of 350,000 Shares at HKD 9.77 Each

Alphamab Oncology has filed a Next Day Disclosure Return with the Hong Kong Stock Exchange, reporting the repurchase of 350,000 shares at an average price of HKD 9.7708 per share.

Reuters·
HK
09966
+1.90%
Reuters·
HK
09966
+1.90%
Posts
View More